alagebrium has been researched along with Obesity in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kersten, JR; LaDisa, JF; Passerini, AG; Rajamani, A; Schrepfer, S; Toth, JM; Wang, H; Weihrauch, D | 1 |
| Andrikopoulos, S; Bierhaus, A; Chand, V; Cooper, ME; Coughlan, MT; de Courten, B; de Courten, MP; Dougherty, SL; Forbes, JM; Harcourt, BE; Kingwell, BA; Morley, AL; Penfold, SA; Sourris, KC; Thallas-Bonke, V; Thomas, MC; Walker, KZ | 1 |
1 trial(s) available for alagebrium and Obesity
| Article | Year |
|---|---|
Targeted reduction of advanced glycation improves renal function in obesity.
Topics: Adolescent; Adult; Animals; Cross-Over Studies; Diet; Glycation End Products, Advanced; Humans; Inflammation; Kidney; Kidney Diseases; Male; Mice; Mice, Knockout; Middle Aged; Obesity; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Thiazoles; Young Adult | 2011 |
1 other study(ies) available for alagebrium and Obesity
| Article | Year |
|---|---|
Alagebrium inhibits neointimal hyperplasia and restores distributions of wall shear stress by reducing downstream vascular resistance in obese and diabetic rats.
Topics: Animals; Aorta, Abdominal; Collagen; Diabetes Mellitus; Glycation End Products, Advanced; Graft Occlusion, Vascular; Male; Neointima; Obesity; Rats; Rats, Zucker; Receptor for Advanced Glycation End Products; Shear Strength; Stents; Stress, Mechanical; Thiazoles; Transforming Growth Factor beta; Vascular Resistance | 2015 |